Insilico Medicine vs Elevance Health

Side-by-side comparison of AI visibility scores, market position, and capabilities

Elevance Health leads in AI visibility (92 vs 43)
Insilico Medicine logo

Insilico Medicine

ChallengerHealthcare Tech

Drug Discovery & Development

Insilico Medicine (HKEX: 3696) raised $293M, posted $56.2M revenue in 2025, and inked a $2.75B Eli Lilly deal in 2026 using generative AI to discover drug targets in cancer and CNS.

AI VisibilityBeta
Overall Score
C43
Category Rank
#1 of 1
AI Consensus
66%
Trend
up
Per Platform
ChatGPT
39
Perplexity
46
Gemini
38

About

Insilico Medicine is a clinical-stage biotechnology company founded in 2014 that leverages generative AI for drug discovery and development. Headquartered in Boston with offices in Hong Kong and New York, the company has built AI platforms utilizing deep generative models, reinforcement learning, and transformers to discover novel drug targets and generate molecular structures with desired properties. Its pipeline spans cancer, fibrosis, CNS diseases, infectious diseases, autoimmune conditions, and aging-related diseases.

Full profile
Elevance Health logo

Elevance Health

LeaderHealthcare Tech

Enterprise

Indianapolis BCBS managed care (NYSE: ELV) ~$175B FY2024 revenue; Anthem renamed 2022, BCBS exclusive in 14 states, Carelon health services, Medicaid/MA medical cost pressure competing with UnitedHealth and Cigna.

AI VisibilityBeta
Overall Score
A92
Category Rank
#194 of 290
AI Consensus
68%
Trend
down
Per Platform
ChatGPT
88
Perplexity
88
Gemini
88

About

Elevance Health, Inc. (formerly Anthem, Inc.) is an Indianapolis, Indiana-based managed care and health services company — publicly traded on the New York Stock Exchange (NYSE: ELV) as an S&P 500 Health Care component — providing health insurance plans under the Blue Cross Blue Shield brand in 14 states (Indiana, Georgia, California, Colorado, Connecticut, Kentucky, Maine, Missouri, Nevada, New Hampshire, New York, Ohio, Virginia, Wisconsin), Medicare Advantage, Medicaid managed care, and commercial employer-sponsored health plans through Carelon (pharmacy and behavioral health services — formerly IngenioRx) to approximately 47 million medical members through approximately 100,000 employees. In fiscal year 2024, Elevance Health reported revenues of approximately $175 billion (predominantly premium revenues from employer-sponsored and government-program health plan members), with operating income under pressure from medical cost increases in the Medicaid segment (post-COVID health utilization normalization causing medical costs to exceed Medicaid actuarial pricing expectations set during the pandemic period of reduced care utilization). CEO Gail Boudreaux has executed the company's transformation from Anthem to Elevance Health (rebranded June 2022) — reflecting the broadened value proposition beyond health insurance into health services: Carelon Services (behavioral health, pharmacy benefit management, utilization management, home health services for both Elevance and external health plan clients) represents the strategy of building a health services ecosystem that retains value within the Elevance enterprise rather than paying external PBMs, behavioral health managers, and care management vendors.

Full profile

AI Visibility Head-to-Head

43
Overall Score
92
#1
Category Rank
#194
66
AI Consensus
68
up
Trend
down
39
ChatGPT
88
46
Perplexity
88
38
Gemini
88
48
Claude
86
35
Grok
99

Key Details

Category
Drug Discovery & Development
Enterprise
Tier
Challenger
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only Insilico Medicine
Drug Discovery & Development

Integrations

Only Elevance Health
Insilico Medicine is classified as company. Elevance Health is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.